To include your compound in the COVID-19 Resource Center, submit it here.

Supreme Court hears Merck label preemption case

Merck & Co. Inc. (NYSE:MRK) received support during oral arguments Monday from at least four Supreme Court justices regarding its position that FDA’s rejection of a proposed warning about the company’s Fosamax alendronate precludes failure-to-warn suits filed in state courts. Two justices, however, suggested that Merck may have

Read the full 481 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers